<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        9-5098-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PANZYGA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HUMAN IMMUNOGLOBULIN PROTEINS
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4482.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OCTAPHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OCTAPHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OCTAPHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J06BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Panzyga is</p><p>Panzyga is a human normal immunoglobulin (IgG) solution (i.e. solution of human antibodies) for intravenous administration (i.e. infusion into a vein). Immunoglobulins are normal constituents of the human blood and support the immune defence of your body. Panzyga contains all IgG which are present in the human blood of healthy people. Adequate doses of Panzyga may restore abnormally low IgG levels to the normal range.</p><p>Panzyga has a broad spectrum of antibodies against various infectious agents.</p><p>What Panzyga is used for</p><p>Panzyga is used for the treatment of children and adults (replacement therapy). There are 4 groups of patients where replacement therapy is used:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with inborn deficiency of antibodies (primary immunodeficiency syndromes, such as:</p><p>congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiencies)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with diseases of the blood that lead to a lack of antibodies and to recurrent infections (Myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients who have low levels of immunoglobulins after the transplantation of stem cells</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with congenital AIDS who have repeated bacterial infections</p><p>Panzyga can be further used in the treatment of inflammatory disorders (immunomodulation). There are 3 groups of patients:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with immune thrombocytopenia (ITP), a condition where the platelets get destroyed and are therefore reduced in number, and who have a high risk of bleeding or need to correct the platelet count prior to surgery</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with Kawasaki disease, a condition that leads to inflammation of various organs</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with Guillain Barr&eacute; syndrome, a condition that leads to inflammation of certain parts of the nervous system</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do NOT use Panzyga:</strong></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to human normal immunoglobulin or any of the other ingredients contained in Panzyga (listed in section 6).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a deficiency of immunoglobulin A (IgA deficiency) and if you have developed antibodies against immunoglobulins of the type IgA.</p><p><strong>Warnings and precautions </strong>Talk to your doctor or pharmacist before using Panzyga.</p><p>Certain adverse reactions may occur more frequently:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of high rate of infusion</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when you receive Panzyga for the first time or, in rare cases, when there has been a long interval since the previous infusion.</p><p>In the case of an adverse reaction, your doctor will either reduce the rate of administration or stop the infusion. The treatment of the adverse event required will depend on the nature and severity of the adverse event.</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_62746" o:spid="_x0000_s1038" style='width:118pt;height:24.25pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="14986,3078" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Picture_x0020_62733" o:spid="_x0000_s1039" type="#_x0000_t75"
  style='position:absolute;width:3078;height:3078;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/SA1ALAS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_62737" o:spid="_x0000_s1040" type="#_x0000_t75"
  style='position:absolute;left:11907;width:3079;height:3078;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/SA1ALAS/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
   o:title=""/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--></p><p>Circumstances and conditions increasing the risk of having side effects</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you had kidney problems in the past or if you have certain risk factors like diabetes, overweight, or age over 65, Panzyga should be administered as slow as possible because cases of acute kidney failure have been reported in patients with such risk factors. Tell your doctor, even when any of the abovementioned circumstances had happened to you in the past.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thromboembolic events such as heart attack, stroke, and obstructions of a deep vein for example in the calves or of a blood vessel in the lung may occur very rarely after administration of Panzyga. These types of events occur more commonly in patients with risk factors, such as obesity, advanced age, high blood pressure, diabetes, previous occurrences of such events, prolonged periods of immobilisations, and intake of certain hormones (e.g. the pill). Ensure a balanced fluid intake; moreover Panzyga should be administered as slow as possible.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions are rare, but can induce an anaphylactic shock, even in patients who had tolerated the previous treatments.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Strong headaches and neck stiffness may rarely occur several hours to 2 days following Panzyga treatment.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with blood group A, B or AB as well as patients with certain inflammatory conditions have a higher risk of red blood cells being destroyed by the administered immunoglobulins (called haemolysis).</p><p>Effects on blood tests</p><p>Panzyga contains a wide variety of different antibodies, some of which can affect blood tests. If you have a blood test after receiving Panzyga, please inform the person taking your blood or your doctor that you have received the human normal immunoglobulin.</p><p>Virus safety</p><p>When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; testing of each donation and pools of plasma for signs of virus/infections</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; steps included by the manufacturers in the processing of the blood or plasma that can inactivate or remove viruses.</p><p>Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections. The measures taken are considered effective for encapsulated viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus and for the non-encapsulated viruses such as hepatitis A virus and parvovirus B19. Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in the product, are protective.</p><p>It is strongly recommended that every time you receive a dose of Panzyga the name and batch number of the product are recorded in order to maintain a record of the batches used.</p><p>Children and adolescents</p><p>There are no specific or additional warnings or precautions applicable for children and adolescents.</p><p>Other medicines and Panzyga</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription, or if you have received a vaccination in the last three months.</p><p>Panzyga may impair the effect of live attenuated virus vaccines such as</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; measles</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rubella &ndash; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mumps</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; varicella.</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_39736" o:spid="_x0000_s1035" style='position:absolute;left:0;
  text-align:left;margin-left:1211.55pt;margin-top:984.8pt;width:21pt;height:21pt;
  z-index:251658240;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="266688,266693" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:shape id="Shape_x0020_1374" o:spid="_x0000_s1036" style='position:absolute;
   top:76200;width:0;height:190493;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="0,190493" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,190493l,e" filled="f" strokeweight=".25pt">
   <v:stroke miterlimit="83231f" joinstyle="miter"/>
   <v:path arrowok="t" textboxrect="0,0,0,190493"/>
  </v:shape><v:shape id="Shape_x0020_1376" o:spid="_x0000_s1037" style='position:absolute;
   left:76200;width:190488;height:0;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="190488,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m190488,l,e" filled="f" strokeweight=".25pt">
   <v:stroke miterlimit="83231f" joinstyle="miter"/>
   <v:path arrowok="t" textboxrect="0,0,190488,0"/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page" anchory="page"/>
 </v:group><v:group id="Group_x0020_39737" o:spid="_x0000_s1032" style='position:absolute;
  left:0;text-align:left;margin-left:0;margin-top:984.8pt;width:21pt;height:21pt;
  z-index:251659264;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="266700,266693" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:shape id="Shape_x0020_1375" o:spid="_x0000_s1033" style='position:absolute;
   left:266700;top:76200;width:0;height:190493;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="0,190493" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,190493l,e" filled="f" strokeweight=".25pt">
   <v:stroke miterlimit="83231f" joinstyle="miter"/>
   <v:path arrowok="t" textboxrect="0,0,0,190493"/>
  </v:shape><v:shape id="Shape_x0020_1377" o:spid="_x0000_s1034" style='position:absolute;
   width:190500;height:0;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="190500,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m190500,l,e" filled="f" strokeweight=".25pt">
   <v:stroke miterlimit="83231f" joinstyle="miter"/>
   <v:path arrowok="t" textboxrect="0,0,190500,0"/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page" anchory="page"/>
 </v:group><![endif]--></p><p>&nbsp;</p><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />After administration of this product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year.</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to become pregnant, ask your doctor or pharmacist if you can get or continue with Panzyga.</p><p>Driving and using machines</p><p>The ability to drive and operate machines may be impaired by some adverse reactions associated with Panzyga. Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.</p><p>Panzyga contains sodium</p><p>This medicinal product contains not more than 0.03 mmol (or 0.69 mg) sodium per ml. To be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will decide if you need Panzyga and at what dose. Panzyga is administered as an intravenous infusion (infusion into a vein) by healthcare personnel. The dose and dosage regimen is dependent on the indication and may need to be individualised for each patient.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p><p>Use in children and adolescents</p><p>The administration of Panzyga in children and adolescents (intravenously) does not differ from the administration in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Contact your doctor as soon as possible if you suffer from any of the serious side effects listed below (<strong>all are very rare </strong>and may affect up to 1 in 10,000 infusions). In some cases your doctor may need to interrupt treatment and reduce your dose or stop treatment:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Swelling</strong> <strong>of the face, tongue and windpipe</strong> that can cause great difficulty in breathing</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>A sudden allergic reaction</strong> with shortness of breath, rash, wheezing and drop of blood pressure</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Stroke</strong> that may cause weakness and / or loss of sensation down one side of the body</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart attack</strong> causing chest pain</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood clot </strong>causing pain and swelling of limbs</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood clot in lung</strong> causing chest pain and breathlessness</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Anaemia</strong> causing shortness of breath or looking pale</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Severe kidney disorder</strong> that may cause you to not pass urine &ndash; &nbsp; <strong>Meningitis</strong> causing strong headache</p><p>If you experience any of the symptoms above, contact your doctor as soon as possible.</p><p>The following other side effects have also been reported:</p><p><strong>Common side effects</strong> (may affect up to 1 in 10 infusions):</p><p>Headache, nausea, fever</p><p><strong>Uncommon side effects</strong> (may affect up to 1 in 100 infusions):</p><p>Skin rash, back pain, chest pain, chills, dizziness, feeling tired, cough, vomiting, belly pain, joint pain, muscle pain, infusion site itching, reduced sense of touch or sensation, reduction of red blood cells, reduction of white blood cells, aseptic meningitis, eye itching, fast beating of the heart, increased blood pressure, ear pain, stiffness, feeling cold, changes in blood tests that report on how the liver is working.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of the month. Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Keep the container in the outer carton in order to protect from light. Do not freeze.</p><p>The product may be removed from the refrigerator for a period of 6 months (without exceeding the expiry date) and stored above +8&deg;C and below +25&deg;C. At the end of this period, the product should not be refrigerated again and should be disposed of. The date at which the product was taken out of the refrigerator should be recorded on the outer carton.</p><p>Do not use this medicine if you notice that the solution is cloudy, has deposits or is coloured intensively.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&ndash; The active substance is human normal immunoglobulin. Panzyga contains 100 mg/ml human protein of which at least 95% is immunoglobulin G (IgG). &ndash; The other ingredients are glycine and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Panzyga is a solution for infusion and is available in vials (1 g/10 ml, 2.5 g/25 ml) or bottles (5 g/50 ml, 10 g/100 ml, 20 g/200 ml, 30 g/300 ml). 
Pack sizes:
1 vial (1 g/10 ml; 2.5 g/25 ml)
1 bottle (5 g/50 ml; 10 g/100 ml; 20 g/200 ml; 30 g/300 ml) The solution is clear or slightly opalescent, colourless or slightly yellow. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>OCTAPHARMA AG Seidenstrasse 2, 8853 Lachen, Switzerland</p><p>Manufacturer</p><p>Octapharma</p><p>72 rue du Mar&eacute;chal Foch, 67380 Lingolsheim, France</p><p>Octapharma Pharmazeutika Produktionsges.m.b.H. Oberlaaer Strasse 235, 1100 Vienna, Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 02/2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هو بانزيجا<br />أي محلول يحتوي على الأجسام ( )IgG بانزيجا هو محلول مناعي طبيعي )أي جي جي<br />المضادة البشرية( يُعطَى عن طريق الوريد )أي بالتسريب الوريدي(. الغلوبولينات المناعية<br />هي من المكونات الطبيعية للدم البشري وتدعم الدفاع المناعي في جسمك. يحتوي بانزيجا<br />الموجودة في الدم البشري عند الأشخاص الأصحاء. قد تعمل IgG على جميع أنواع<br />المنخفضة بشكل غير طبيعي إلى IgG الجرعات الكافية من بانزيجا على رفع مستويات<br />المستوى الطبيعي.<br />يحتوي بانزيجا على مجموعة واسعة من الأجسام المضادة ضد مختلف العوامل المُعدية.<br />ما هي دواعي استخدام بانزيجا<br />يُستخدم بانزيجا في علاج الأطفال والبالغين )العلاج التعويضي(. يُستخدم العلاج التعويضي<br />لدى 4 مجموعات من المرضى:<br />&bull; المرضى الذين يعانون من نقص خَلقي في الأجسام المضادة في الدم )متلازمات نقص<br />المناعة الأولية، مثل: فَقْد غاماغلوبولين الدم الخَلقي و نقص غاماغلوبولين الدم الخَلقي،<br />نقص المناعة الشائع المُتغير، نقص المناعة المشترك الشديد(<br />&bull; المرضى الذين يعانون من أمراض الدم التي تؤدي إلى فقدان الأجسام المضادة<br />أو سرطان الدم الليمفاوي المزمن مع نقص &raquo; ورم النخاع &laquo; والالتهابات المتكررة )مايلوما<br />غاماغلوبولين الثانوي والالتهابات المتكررة(<br />&bull; المرضى الذين لديهم مستويات منخفضة من الغلوبولين المناعي بعد زرع الخلايا<br />الجذعية<br />الخَلقي الذين يعانون من التهابات &raquo; الإيدز &laquo; &bull; المرضى المصابون بنقص المناعة المكتسب<br />بكتيرية متكررة<br />كما يمكن أن يُستخدم بانزيجا كذلك في علاج الاضطرابات الالتهابية )التعديل المناعي(.<br />هناك 3 مجموعات من المرضى:<br />وهي حالة يتم ،)ITP &bull; المرضى الذين يعانون من نقص الصُّفيْحات المناعي )أي تي بي<br />فيها تدمير الصفائح الدموية وبالتالي ينخفض عددها، والمعرضون لخطر كبير من<br />حدوث النزيف أو ممن يحتاجون إلى زيادة عدد الصفائح الدموية قبل الجراحة<br />&bull; المرضى المصابون بمرض كاواساكي، وهو حالة تُؤدي إلى التهاب في مختلف أجهزة<br />الجسم<br />&bull; المرضى الذين يعانون من متلازمة غيلان باريه، وهي حالة تُؤدي إلى التهاب أجزاء<br />معينة من الجهاز العصبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم بانزيجا:<br />&bull; إذا كان لديك حساسية نحو الغلوبولين المناعي الطبيعي البشري أو نحو أي من المكوّنات<br />.) الأخرى الموجودة في بانزيجا )المدرجة في الفقرة رقم 6<br />وإذا ظهرت لديك )IgA نقص أي جي إيه ( A &bull; إذا كان لديك نقص في الغلوبولين المناعي<br />.IgA أجسام مضادة للغلوبولين المناعي من نوع<br />المحاذير والإحتياطات<br />تحدث مع طبيبك أو الصيدلي قبل استخدام بانزيجا.<br />قد تحدث ردود فعل سلبية معينة بشكل أكثر تكرارية في الحالات التالية:<br />&bull; في حالة ارتفاع معدل التسريب الوريدي<br />&bull; عندما تتلقى بانزيجا للمرة الأولى أو، في حالات نادرة، عند مرور فترة زمنية طويلة<br />على تلقيك الجرعة السابقة بالتسريب الوريدي.<br />في حالة تعرّضك لرد فعل سلبي، سيقوم الطبيب إما بخفض معدل التسريب الوريدي أو<br />بإيقافه تمامًا. يعتمد نوع علاج الأثر السلبي المطلوب على طبيعة ذلك الأثر السلبي وشدته.<br />الظروف والحالات التي تزيد من خطر حدوث الآثار الجانبية<br />&bull; إذا سبق وعانيت من مشاكل في الكلى في الماضي أو إذا كان لديك بعض عوامل الخطر<br />مثل مرض السكري أو زيادة الوزن أو تجاوزت 65 عاما من العمر، يجب إعطاء<br />بانزيجا بأبطأ سرعة ممكنة وذلك لأنه تم التبليغ عن حالات من الفشل الكلوي الحاد لدى<br />المرضى الذين يعانون من مثل عوامل الخطر هذه. أخبر طبيبك، حتى إذا تعرضت لأي<br />من الظروف المذكورة أعلاه في الماضي.<br />&bull; قد تحدث حالات نادرة جدًا من الانسداد الخثاري مثل النوبات القلبية والسكتة الدماغية<br />وانسداد أحد الأوردة العميقة على سبيل المثال في ربلة الساق أو في الأوعية الدموية في<br />الرئة بعد تناول بانزيجا. تحدث هذه الأنواع من الأحداث بشكل أكثر شيوعا لدى<br />المرضى الذين يعانون من عوامل الخطر، مثل السمنة، والعمر المتقدم، وارتفاع ضغط<br />الدم، والسكري، وممن تعرضوا في السابق لمثل هذه العوامل، وكذلك عدم الحركة<br />لفترات طويلة، واستخدام بعض الهرمونات )على سبيل المثال حبوب منع الحمل(.<br />احرص على تناول كمية متوازنة من السوائل، بالإضافة إلى أنه ينبغي إعطاء بانزيجا<br />بأبطأ سرعة ممكنة في هذه الحالات.<br />&bull; ردود الفعل التحسسية نادرة الحدوث، ولكن يمكن أن يُحفّز إعطاء بانزيجا حدوث<br />الصدمة التأقيّة، حتى لدى المرضى الذين سبق لهم العلاج ببانزيجا.<br />&bull; قد يحدث بشكل نادر صداع شديد وتصلّب في الرقبة بعد تلقي بانزيجا بعدة ساعات إلى<br />يومين.<br />وكذلك المرضى الذين يعانون من بعض AB أو B ،A &bull; المرضى من ذوي فصيلة الدم<br />الحالات الالتهابية معرضون أكثر لخطر حدوث تدمير لخلايا الدم الحمراء بسبب تلقّي<br />الجلوبولين المناعي )حالة تُسمى انحلال الدم(.<br />الآثار على فحوص الدم<br />بانزيجا يحتوي على مجموعة واسعة من الأجسام المضادة المختلفة، يمكن أن تؤثر بعضها<br />على فحوص الدم. إذا كنت ستقوم بفحص دم بعد تلقّي بانزيجا، يُرجى إبلاغ الشخص الذي<br />يقوم بسحب الدم أو طبيبك بأنك قد تلقيت العلاج بالجلوبولين المناعي البشري الطبيعي.<br />سلامة المُنتج من الفيروسات<br />عند تصنيع الأدوية من الدم البشري أو البلازما، يتم وضع تدابير معينة لمنع انتقال العدوى<br />إلى المرضى. وتشمل هذه التدابير ما يلي:<br />&bull; الاختيار الدقيق للأشخاص المانحين للدم والبلازما للتأكد من استبعاد أولئك المعرضين<br />لخطر العدوى<br />&bull; فحص كل دم متبرع به وتجميعات البلازما لوجود أي مؤشر للفيروس / العدوى<br />&bull; الخطوات التي تقوم بها الشركات المُصنعة في معالجة الدم أو البلازما والتي يمكن أن<br />تعمل على تعطيل أو إزالة الفيروسات.<br />وعلى الرغم من هذه التدابير، لا يمكن استبعاد إمكانية انتقال العدوى تماما عند إعطاء<br />المنتجات الطبيّة المُعدّة من الدم البشري أو البلازما. وهذا ينطبق أيضا على أي فيروسات<br />غير معروفة أو ناشئة أو أنواع أخرى من العدوى.<br />وتعتبر التدابير المُتّخذة فعّالة بالنسبة للفيروسات المُغلّفة مثل فيروس نقص المناعة البشرية<br />والفيروسات الغير مُغلّفة C وفيروس التهاب الكبد الوبائي B وفيروس التهاب الكبد الوبائي<br />.B وبارفوفيروس 19 A مثل فيروس التهاب الكبد<br />أو التهابات بارفوفيروس A لم يرتبط إعطاء الجلوبيولين المناعي بحدوث التهاب الكبد<br />ربما لأن الأجسام المضادة ضد هذه الالتهابات، والموجودة في المنتج، تعمل على B19<br />الوقاية من الإصابة بها.<br />من المستحسن أن يتم تسجيل اسم ورقم تشغيل المنتج في كل مرة تتلقى فيها جرعة من<br />بانزيجا من أجل الحفاظ على سجلّ التشغيلات المستخدمة.<br />الأطفال والمراهقين<br />لا توجد تحذيرات أو احتياطات خاصة أو إضافية تنطبق على الأطفال والمراهقين.<br />أدوية أخرى و بانزيجا<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أو قد تتناول أي أدوية أخرى،<br />بما في ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية، أو إذا كنت قد تلقيت أي<br />تطعيم خلال الأشهر الثلاثة الماضية.<br />قد يُضعف بانزيجا من تأثير اللقاحات ضد الفيروسات الحيّة المُضعّفة مثل:<br />&bull; الحصبة<br />&bull; الحصبة الألمانية<br />&bull; النّكاف<br />.&raquo; جدري الماء &laquo; &bull; الحماق<br />بعد إعطاء هذا المنتج، يجب ترك فاصل زمني لمدة 3 أشهر قبل تلقّي أي تطعيم بأحد<br />لقاحات الفيروسات الحيّة المُضعّفة. وفي حالة لقاح الحصبة، قد يستمر تأثير هذا المنتج<br />لمدة تصل إلى سنة واحدة.<br />الحمل، الرضاعة الطبيعية والخصوبة<br />إذا كنت حاملا أو مرضعة، تعتقدين أنك قد تكونين حاملا أو تخططين للحمل، استشيري<br />طبيبك أو الصيدلي إذا كان بإمكانك تلقّي أو الاستمرار بتلقي العلاج ببانزيجا.<br />القيادة واستخدام الآلات<br />قد تتأثر القدرة على قيادة وتشغيل الآلات ببعض ردود الفعل السلبية المرتبطة ببانزيجا.<br />يجب على المرضى الذين يعانون من ردود فعل سلبية أثناء العلاج الانتظار حتى يتخلصون<br />من هذه الآثار قبل القيادة أو تشغيل الآلات.<br />بانزيجا يحتوي على الصوديوم<br />هذا المنتج الطبي يحتوي على أكثر من 0.03 مليمول )أو 0.69 مجم( من الصوديوم في<br />كل ملل. ينبغي أن يُؤخذ ذلك بعين الاعتبار من قبل المرضى الذين يخضعون لحمية<br />الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سوف يقرر طبيبك إذا كنت بحاجة إلى العلاج ببانزيجا وكذلك مقدار الجرعة التي تحتاجها.<br />يُعطى بانزيجا عن طريق الحقن بالتسريب الوريدي )التسريب في الوريد( من قبل موظفي<br />الرعاية الصحية. تعتمد الجرعة ونظام إعطائها على الحالة الطبيّة المرادُ علاجها وقد تُحدد<br />بشكل فرديّ لكل مريض.<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.<br />استخدامه لدى الأطفال والمراهقين<br />لا تختلف طريقة إعطاء بانزيجا لدى الأطفال والمراهقين )بالتسريب الوريدي( عما هي<br />عليه لدى البالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع سائر الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، وإن كانت لا تحدث<br />لدى جميع من يتلقّاه.<br />اتصل بطبيبك في أقرب وقت ممكن إذا واجهت أي من الآثار الجانبية الخطيرة المدرجة<br />أدناه )كلها نادرة جدا ويمكن أن تؤثر على ما يصل إلى 1 في 10،000 متلقٍ(. في بعض<br />الحالات قد یحتاج طبیبك إلی مقاطعة العلاج وتقلیل الجرعة أو إيقاف العلاج بشكل تام:<br />&bull; تورم في الوجه واللسان ومجرى التنفّس الذي يمكن أن يُسبب صعوبة كبيرة في التنفس<br />&bull; رد فعل تحسسي مفاجئ مع ضيق في التنفس، والطفح الجلدي، والصفير مع التنفس<br />وانخفاض ضغط الدم<br />&bull; السكتة الدماغية التي قد تسبب ضعف و / أو فقدان الإحساس في جانب واحد من الجسم<br />&bull; نوبة قلبية تسبب ألم في الصدر<br />&bull; تجلط الدم الذي يسبب ألم وتورم في الأطراف<br />&bull; تجلط الدم في الرئة مما يُسبب ألم في الصدر وضيق في التنفس<br />&bull; فقر الدم يُسبب ضيق في التنفس أو الشحوب<br />&bull; اضطراب الكلى الحاد الذي قد يؤدي بك إلى عدم القدرة على إخراج البول<br />&bull; التهاب السحايا الذي يُسبب صداعا قويا<br />إذا واجهت أي من الأعراض المذكورة أعلاه، اتصل بطبيبك في أقرب وقت ممكن.<br />كما تم الإبلاغ عن الآثار الجانبية الأخرى التالية:<br />الآثار الجانبية الشائعة )قد تؤثر على ما يصل إلى 1 في 10 مُتلقّ(:<br />الصداع، والغثيان، والحمى<br />آثار جانبية غير شائعة )قد تؤثر على ما يصل إلى 1 في 100 مُتلقّ(:<br />طفح جلدي، وآلام في الظهر، وألم في الصدر، وقشعريرة، ودوخة، وشعور بالتعب،<br />والسعال، والقيء، وآلام في البطن، وآلام المفاصل، وآلام في العضلات، وحكّة في موضع<br />التسريب، وتدني في حاسة اللمس أو في الإحساس، وانخفاض في عدد خلايا الدم الحمراء،<br />وحكّة ،&raquo; المُسبّب بالأدوية &laquo; وانخفاض في عدد خلايا الدم البيضاء، والتهاب السحايا العقيم<br />في العين، وتسارع ضربات القلب، وزيادة ضغط الدم، وآلام الأذن، والتيبّس، والشعور<br />بالبرد، وتغيرات في نتائج فحوص الدم الخاصة بوظائف الكبد.<br />الإبلاغ عن الآثار الجانبية<br />إذا تعرّضت لأي آثار جانبية، تحدث مع طبيبك أو الصيدلي. ويشمل ذلك أي آثار جانبية<br />محتملة غير مدرجة في هذه النشرة. إبلاغك عن الآثار الجانبية يمكن أن يساعد في توفير<br />مزيد من المعلومات حول سلامة هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بهذا الدواء بعيدا عن مرأى ومتناول األطفال.<br />لا يجوز استخدام هذا الدواء بعد تاريخ انتهاء الصلاحيّة المُدرج على المُلصق والكرتون.<br />يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر.<br />8 درجة مئوية(. احتفظ بالعبوة داخل الكرتون الخارجي من أجل - خزنه في الثلاجة ) 2<br />حمايتها من الضوء.<br />لا تجمّده.<br />يمكن الاحتفاظ بهذا المنتج خارج الثلاجة لمدة 6 أشهر )دون تجاوز تاريخ انتهاء<br />الصلاحية( في درجة حرارة أعلى من 8 درجة مئوية وأقل من 25 درجة مئوية. في نهاية<br />هذه الفترة، لا ينبغي إعادة المنتج إلى الثلاجة مرة أخرى ويجب التخلص منه. يجب تسجيل<br />التاريخ الذي تم فيه إخراج المنتج من الثلاجة على الكرتون الخارجي.<br />لا تستخدم هذا الدواء إذا لاحظت أن المحلول معكّر، يحتوي على ترسّبات أو متلوّن بكثافة.<br />لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل<br />الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. من شأن هذه التدابير أن<br />تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي الغلوبولين المناعي الطبيعي البشري. يحتوي بانزيجا على 100 مجم /<br />.٪ فيه عن 95 )IgG( G ملل من البروتين البشري الذي لا تقل نسبة الغلوبولين المناعي<br />&bull; المكونات الأخرى هي الجلايسين والماء المُخصّص للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو محلول بانزيجا وما هي محتويات العبوة:<br />بانزيجا هو محلول مُعد للحقن بالتسريب الوريدي ويتوفر في قوارير صغيرة ) 1 جم / 10<br />ملل، 2.5 جم / 25 ملل( أو قوارير كبيرة ) 5 جم / 50 ملل، 10 جم / 100 ملل، 20 جم /<br />200 ملل، 30 جم / 300 ملل (.<br />أحجام العبوة:<br />1 قارورة صغيرة ) 1 جم / 10 ملل؛ 2.5 جم / 25 ملل(<br />1 قارورة كبيرة ) 5 جم / 50 ملل؛ 10 جم / 100 ملل؛ 20 جم / 200 ملل؛ 30 جم / 300<br />ملل(<br />المحلول صافٍ أو غميم قليلا، عديم اللون أو يميل إلى اللون الأصفر قليلا.<br />قد لا تُسوّق جميع أحجام العبوة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>أوكتافارما إيه جي<br />3588 لاخين، سويسرا ، طريق زايدن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت الموافقة الأخيرة على هذه النشرة في 02/2017 م.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Panzyga, 100 mg/ml solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Human normal immunoglobulin (IVIg)
One ml contains:
Human normal immunoglobulin………………….100 mg
(Purity of at least 95 % IgG)

Each vial of 10 ml contains: 1 g of human normal immunoglobulin.
Each vial of 25 ml contains: 2.5 g of human normal immunoglobulin.
Each bottle of 50 ml contains: 5 g of human normal immunoglobulin.
Each bottle of 100 ml contains: 10 g of human normal immunoglobulin.
Each bottle of 200 ml contains: 20 g of human normal immunoglobulin.
Each bottle of 300 ml contains: 30 g of human normal immunoglobulin.
Distribution of the IgG subclasses (approx. values):
IgG1		65 % 
IgG2		28 %
IgG3		3 %
IgG4		4 %
The maximum IgA content is 300 micrograms/ml

Produced from the plasma of human donors.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion
The solution is clear or slightly opalescent and colourless or pale yellow. The pH of the solution is 4.5 to 5.0, the osmolality is ≥ 240 mosmol/kg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Replacement therapy in adults, and children and adolescents (0-18 years) in:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary immunodeficiency (PID) syndromes with impaired antibody production (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital AIDS with recurrent bacterial infections.</p><p><u>Immunomodulation in adults, and children and adolescents (0-18 years) in:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guillain Barr&eacute; syndrome.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kawasaki disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Replacement therapy should be initiated and monitored under the supervision of a physician experienced in the treatment of immunodeficiency.</p><p><u>Posology</u></p><p>The dose and dose regimen is dependent on the indication.</p><p>In replacement therapy the dose may need to be individualised for each patient dependent on the pharmacokinetic and clinical response. The following dose regimens are given as a guideline.</p><p><em>Replacement therapy in primary immunodeficiency (PID) syndromes</em></p><p>The dose regimen should achieve a trough level of IgG (measured before the next infusion) of at least 5-6 g/l. Three to six months are required after the initiation of therapy for equilibration to occur. The recommended starting dose is 0.4&ndash;0.8 g/kg given once, followed by at least 0.2 g/kg given every three to four weeks.</p><p>The dose required to achieve a trough level of 5&ndash;6 g/l is of the order of 0.2‑0.8&nbsp;g/kg/month. The dosage interval when steady state has been reached varies from 3&nbsp;‑&nbsp;4&nbsp;weeks.</p><p>Trough levels should be measured and assessed in conjunction with the incidence of infection. To reduce the rate of infection, it may be necessary to increase the dosage and aim for higher trough levels.</p><p><em>Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed; hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation; congenital AIDS with recurrent bacterial infections</em></p><p>The recommended dose is 0.2&ndash;0.4 g/kg every three to four weeks.</p><p><em>Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation</em></p><p>The recommended dose is 0.2&ndash;0.4 g/kg every three to four weeks. The trough levels should be maintained above 5 g/l.</p><p><em>Primary immune thrombocytopenia (ITP)</em></p><p>There are two alternative treatment schedules:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.8&ndash;1g/kg given on day one; this dose may be repeated once within 3 days</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.4 g/kg given daily for two to five days.</p><p>The treatment can be repeated if relapse occurs.</p><p><em>Guillain Barr&eacute; syndrome</em></p><p>0.4 g/kg/day over 5 days.</p><p><em>Kawasaki Disease</em></p><p>1.6&ndash;2.0 g/kg should be administered in divided doses over two to five days or 2.0 g/kg as a single dose. Patients should receive concomitant treatment with acetylsalicylic acid.</p><p>The dosage recommendations are summarised in the following table:</p><table border="1" cellspacing="0" cellpadding="0" style="width:600px"><thead><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Frequency of injection</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Replacement therapy in primary immunodeficiency</p></td><td style="vertical-align:top"><p>starting dose:<br />0.4&ndash;0.8 g/kg<br />thereafter:<br />0.2&ndash;0.8 g/kg</p></td><td style="vertical-align:top"><p><br /><br />every 3&ndash;4 weeks to obtain IgG trough level of at least 5&ndash;6 g/l</p></td></tr><tr><td style="vertical-align:top"><p>Replacement therapy in secondary immunodeficiency</p></td><td style="vertical-align:top"><p>0.2&ndash;0.4 g/kg<br />&nbsp;</p></td><td style="vertical-align:top"><p>every 3&ndash;4 weeks to obtain IgG trough level of at least 5&ndash;6 g/l</p></td></tr><tr><td style="vertical-align:top"><p>Congenital AIDS</p></td><td style="vertical-align:top"><p>0.2&ndash;0.4 g/kg</p></td><td style="vertical-align:top"><p>every 3&ndash;4 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Hypogammaglobulinaemia (&lt;4&nbsp;g/l) in patients after allogeneic haematopoietic stem cell transplantation</p></td><td style="vertical-align:top"><p>0.2&ndash;0.4 g/kg</p></td><td style="vertical-align:top"><p>every 3&ndash;4 weeks to obtain IgG trough levels above 5&nbsp;g/l.</p></td></tr><tr><td style="vertical-align:top"><p>Immunomodulation:</p><p>Primary immune thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.8&ndash;1 g/kg<br />or<br />0.4 g/kg/d</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>on day 1, possibly repeated once within 3 days<br />for 2&ndash;5 days</p></td></tr><tr><td style="vertical-align:top"><p>Guillain Barr&eacute; syndrome</p></td><td style="vertical-align:top"><p>0.4 g/kg/d</p></td><td style="vertical-align:top"><p>for 5 days</p></td></tr><tr><td style="vertical-align:top"><p>Kawasaki disease</p></td><td style="vertical-align:top"><p>1.6&ndash;2 g/kg<br />or</p><p><br />2 g/kg</p></td><td style="vertical-align:top"><p>in divided doses over 2&ndash;5 days in association with acetylsalicylic acid;</p><p><br />in one dose in association with acetylsalicylic acid</p></td></tr></tbody></table><p><em>Paediatric population</em></p><p>The posology in children and adolescents (0&ndash;18 years) is not different to that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned conditions.</p><p><u>Method of administration</u></p><p>For intravenous use.</p><p>Human normal immunoglobulin should be infused intravenously at an initial rate of 0.6&nbsp;ml/kg/hr for 30&nbsp;min. If well tolerated (see section 4.4), the rate of administration may gradually be increased to a maximum of 4.8 ml/kg/hr.</p><p>In PID patients who have tolerated the infusion rate of 4.8 ml/kg/hr well, the rate may be further increased gradually to a maximum of 8.4 ml/kg/hr.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients (see section 4.4).
Hypersensitivity to human immunoglobulins, especially in patients with antibodies against IgA.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Certain severe adverse drug reactions may be related to the rate of infusion. The recommended infusion rate given under section 4.2 must be closely followed. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period.</p><p>&nbsp;</p><p>Certain adverse reactions may occur more frequently:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of high rate of infusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients who receive human normal immunoglobulin for the first time or, in rare cases, when the human normal immunoglobulin product is switched or when there has been a long interval since the previous infusion.</p><p>&nbsp;</p><p>Potential complications can often be avoided by ensuring that patients:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are not sensitive to human normal immunoglobulin by initially injecting the product slowly (0.6-1.2 ml/kg/hr).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are carefully monitored for any symptoms throughout the infusion period. In particular, patients naive to human normal immunoglobulin, patients switched from an alternative IVIg product or when there has been a long interval since the previous infusion should be monitored during the first infusion and for the first hour after the first infusion, in order to detect potential adverse signs. All other patients should be observed for at least 20 minutes after administration.</p><p>In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped. The treatment required depends on the nature and severity of the adverse reaction.</p><p>In case of shock, standard medical treatment for shock should be implemented.</p><p>In all patients, IVIg administration requires:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adequate hydration prior to the initiation of the infusion of IVIg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; monitoring of urine output</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; monitoring of serum creatinine levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; avoidance of concomitant use of loop diuretics.</p><p><u>Hypersensitivity</u></p><p>True hypersensitivity reactions are rare. They can occur in patients with anti-IgA antibodies.</p><p>IVIg is not indicated in patients with selective IgA deficiency where the IgA deficiency is the only abnormality of concern.</p><p>Rarely, human normal immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who had tolerated previous treatment with human normal immunoglobulin.</p><p><u>Thromboembolism</u></p><p>There is clinical evidence of an association between IVIg administration and thromboembolic events such as myocardial infarction, cerebral vascular accident (including stroke), pulmonary embolism and deep vein thromboses which is assumed to be related to a relative increase in blood viscosity through the high influx of immunoglobulin in at-risk patients. Caution should be exercised in prescribing and infusing IVIg in obese patients and in patients with pre-existing risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilisation, severely hypovolaemic patients, patients with diseases which increase blood viscosity).</p><p>In patients at risk for thromboembolic adverse reactions, IVIg products should be administered at the minimum rate of infusion and dose practicable.</p><p><u>Acute renal failure</u></p><p>Cases of acute renal failure have been reported in patients receiving IVIg therapy. In most cases, risk factors have been identified, such as pre-existing renal insufficiency, diabetes mellitus, hypovolemia, overweight, concomitant nephrotoxic medicinal products or age over 65.</p><p>In case of renal impairment, IVIg discontinuation should be considered. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IVIg products containing various excipients such as sucrose, glucose and maltose, those containing sucrose as a stabiliser accounted for a disproportionate share of the total number. In patients at risk, the use of IVIg products that do not contain these excipients may be considered. Panzyga does not contain sucrose, maltose or glucose.</p><p>In patients at risk for acute renal failure, IVIg products should be administered at the minimum rate of infusion and dose practicable.</p><p><u>Aseptic meningitis syndrome (AMS)</u></p><p>Aseptic meningitis syndrome has been reported to occur in association with IVIg treatment. Discontinuation of IVIg treatment has resulted in remission of AMS within several days without sequelae. The syndrome usually begins within several hours to 2 days following IVIg treatment. Cerebrospinal fluid studies are frequently positive with pleocytosis up to several thousand cells per mm<sup>3</sup>, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dl.</p><p>AMS may occur more frequently in association with high-dose (2 g/kg) IVIg treatment.</p><p><u>Haemolytic anaemia</u></p><p>IVIg products can contain blood group antibodies which may act as haemolysins and induce <em>in vivo</em> coating of red blood cells with immunoglobulin, causing a positive direct antiglobulin reaction (Coombs&rsquo; test) and, rarely, haemolysis. Haemolytic anaemia can develop subsequent to IVIg therapy due to enhanced red blood cells (RBC) sequestration. IVIg recipients should be monitored for clinical signs and symptoms of haemolysis (see section 4.8).</p><p><u>Interference with serological testing</u></p><p>After injection of immunoglobulin the transitory rise of various passively transferred antibodies in the patient&#39;s blood may result in misleading positive results in serological testing.</p><p>Passive transmission of antibodies to erythrocyte antigens, e.g. A, B, D may interfere with some serological tests for red cell antibodies for example the direct antiglobulin test (DAT, direct Coombs&#39; test).</p><p><u>Transmissible agents</u></p><p>Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.</p><p>The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV and for the non-enveloped viruses HAV and parvovirus B19.</p><p>There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to the viral safety.</p><p>It is strongly recommended that every time that Panzyga is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.</p><p><u>Sodium content</u></p><p>This medicinal product contains not more than 0.03 mmol (or 0.69 mg) sodium per ml. To be taken into consideration by patients on a controlled sodium diet.</p><p><u>Paediatric population</u></p><p>The listed warnings and precautions apply both to adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Live attenuated virus vaccines</u></p><p>Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella. After administration of this medicinal product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year. Therefore, patients receiving measles vaccine should have their antibody status checked.</p><p><u>Paediatric population</u></p><p>The listed interactions apply both to adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. IVIg products have been shown to cross the placenta, increasingly during the third trimester. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected.</p><p><u>Breast-feeding</u></p><p>Immunoglobulins are excreted into the milk and may contribute to protecting the neonate from pathogens which have a mucosal portal of entry.</p><p><u>Fertility</u></p><p>Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to be expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ability to drive and operate machines may be impaired by some adverse reactions associated with Panzyga. Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.</p><p>Rarely human normal immunoglobulins may cause a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.</p><p>Cases of reversible aseptic meningitis and rare cases of transient cutaneous reactions have been observed with human normal immunoglobulin. Reversible haemolytic reactions have been observed in patients, especially those with blood groups A, B, and AB. Rarely, haemolytic anaemia requiring transfusion may develop after high dose IVIg treatment (see also Section 4.4).</p><p>Increase in serum creatinine level and/or acute renal failure have been observed.</p><p>Very rarely: thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, deep vein thromboses.</p><p>For safety information with respect to transmissible agents, see section 4.4.</p><p><u>Tabulated list of adverse reactions</u></p><p>The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).</p><p>Frequencies have been evaluated according to the following convention: very common (&ge;&nbsp;1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>Within each Organ Class, adverse reactions are presented in order of decreasing seriousness.</p><p>Frequency of adverse drug reactions in clinical studies with Panzyga:</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class (SOC) according to the sequence:</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency per Infusion</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Haemolysis&dagger;, anaemia, leukopenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p><p>-----------------------------------------</p><p>Aseptic meningitis, hypoaesthesia, dizziness</p></td><td style="vertical-align:top"><p>Common</p><p>----------------------------</p><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Eye pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Ear pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p><p>-------------------------------------------</p><p>Vomiting, abdominal pain, abdominal discomfort</p></td><td style="vertical-align:top"><p>Common</p><p>----------------------------<br />Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia, myalgia, musculoskeletal pain or stiffness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Pyrexia</p><p>-----------------------------------------</p><p>Chills, chest pain, pain, feeling cold, asthenia, fatigue, infusion site pruritus</p></td><td style="vertical-align:top"><p>Common</p><p>-----------------------------</p><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p>&dagger; subclinical case</p><p>&nbsp;</p><p>The following reactions have been reported to occur with IVIg treatment and can also occur after Panzyga administration:</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p><strong>MedDRA System Organ Class</strong></p></td><td><p><strong>Adverse Reactions</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity, anaphylactic reaction, anaphylactoid reaction, angioneurotic oedema, face oedema</p></td></tr><tr><td style="vertical-align:top"><p>Metabolic and nutritional disorders</p></td><td style="vertical-align:top"><p>Fluid overload, (pseudo)hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Agitation, confusional state, anxiety, nervousness</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Cerebrovascular accident, coma, loss of consciousness, convulsion,encephalopathy, &nbsp;migraine, speech disorder, photophobia, paraesthesia, tremor</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Cardiac arrest, angina pectoris, bradycardia, palpitations, cyanosis</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Peripheral circulatory failure or collapse, phlebitis, pallor</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Respiratory failure, apnoea, acute respiratory distress syndrome, pulmonary oedema, bronchospasm, dyspnoea, hypoxia, wheezing</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Hepatic dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Steven-Johnson syndrome, epidermolysis, skin exfoliation, erythema (multiforme), eczema, urticaria, rash (erythematous), (bullous) dermatitis, pruritus, alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Pain in extremity, neck pain, muscle spasm</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Osmotic nephropathy, renal pain</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site reaction, chest discomfort, hot flush, flu-like illness, feeling hot, flushing, oedema, lethargy, burning sensation, hyperhidrosis, malaise</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Coombs&rsquo; direct test positive, falsely elevated erythrocyte sedimentation rate, oxygen saturation decreased</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Transfusion related acute lung injury (TRALI)</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>For description of selected adverse events, such as hypersensitivity reactions, thromboembolism, acute renal failure, aseptic meningitis syndrome, and haemolytic anaemia, see section 4.4.</p><p><u>Paediatric population</u></p><p>Frequency, type and severity of adverse reactions in children were the same as in adults.</p><p><u>To report any side effect(s):</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Health care professionals are asked to report any suspected adverse reactions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Kingdom of Saudi Arabia:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340</p><p>o&nbsp;&nbsp; Toll free phone: 8002490000</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Other GCC states:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose may lead to fluid overload and hyperviscosity, particularly in patients at risk, including elderly patients or patients with cardiac or renal impairment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: immune sera and immunoglobulins: immunoglobulins, normal human, for intravascular administration, ATC-Code: J06B A02.</p><p>Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents.</p><p>Human normal immunoglobulin contains the IgG antibodies present in the normal population. It is usually prepared from pooled plasma from not fewer than 1000 donations. It has a distribution of immunoglobulin&nbsp;G subclasses closely proportional to that in native human plasma. Adequate doses of this medicinal product may restore abnormally low immunoglobulin G levels to the normal range.</p><p>The mechanism of action in indications other than replacement therapy is not fully elucidated, but includes immunomodulatory effects.</p><p><u>Clinical Studies</u></p><p>A prospective, open-label, non-controlled study was done in 51&nbsp;patients with <u>primary immunodeficiency syndromes</u>. The patients were recruited into 3 age strata (&sup3;2 years and &lt;12 years of age, &sup3;12 years and &lt;16 years of age, and &sup3;16&nbsp;years and &pound;75 years). The primary endpoint of the study was the rate of serious bacterial infections (SBI) per person-year on treatment. Patients received a total of 17 or 13&nbsp;infusions of Panzyga over the course of this study, depending on whether their regular treatment intervals were every 3 or 4 weeks, respectively. The dose was 0.2-0.8 g/kg to be infused at increasing infusion rates up to a maximum of 0.08&nbsp;ml/kg/min. Two patients experienced 4 SBIs. With altogether 49.2 patient exposure years, the result of this primary endpoint was 0.08 SBIs/patient exposure year with an upper 99% confidence interval limit of 0.5. Also the other efficacy parameters calculated by patient exposure year, such as other infections and days with use of antibiotics, absence from school or work, and hospitalised due to infection, were in line with what has been published for other IVIGs previously developed.</p><p>This study was followed by an extension study which was carried out in order to assess the tolerability of Panzyga when administered at higher infusion rates (from 0.08&nbsp;ml/kg/min up to 0.14&nbsp;ml/kg/min). In total, 21 patients were enrolled. The product was well tolerated and all patients completed the study as planned. Study medication related AEs were reported in 2 children and 2&nbsp;adults; the most commonly reported reactions were nausea and headache.</p><p>A further prospective, open-label, non-controlled study was done in 40&nbsp;patients with <u>immune thrombocytopenic purpura</u> of at least 12&nbsp;months duration. Patients received a daily dose of 1&nbsp;g/kg for 2&nbsp;consecutive days. Alternative response (AR) according to the EMA Guideline was defined as an increase in platelet count to &ge;30x10<sup>9</sup>/L and to at least double the baseline platelet count, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding. An AR was observed in 24 patients (66.7%).</p><p>Complete response (CR) according to the EMA Guideline was defined as the achievement of platelet counts &ge;100x10<sup>9</sup>/L, to be fulfilled on at least 2 separate visits at least 7 days apart without new bleedings. CR was observed in 18 patients (50.0%).</p><p>Loss of AR/CR was applied if the criteria for AR/CR were fulfilled but deteriorated afterwards as a decrease in platelet count to &lt;30x10<sup>9</sup>/L (AR) or &lt;100x10<sup>9</sup>/L (CR) or a decrease in platelet count to less than double the baseline count or as occurrence of bleeding. Regarding loss of AR, 11 of 24 patients (45.8%) who fulfilled the AR criteria had a loss of response. Loss of CR was seen for 14 of 18 patients (77.8%) who fulfilled the CR criteria.</p><p>For safety information derived from clinical studies please see Section&nbsp;4.8.</p><p><u>Paediatric Population</u></p><p>There were no major differences in the proportion of children or adolescent patients with AEs compared with adults. AEs related to the system organ class &quot;infections and infestations&quot; were the most commonly AEs met in all age groups; however, they were reported in a higher percentage of children and adolescent patients. The same difference was noted for gastrointestinal disorders AEs. It was also noticed a higher percentage of patients in children age group having AEs from the system organ class &quot;skin and subcutaneous tissue disorders&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Human normal immunoglobulin is immediately and completely bioavailable in the recipient&rsquo;s circulation after intravenous administration. It is distributed relatively rapidly between plasma and extravascular fluid, after approximately 3&ndash;5 days equilibrium is reached between the intra- and extravascular compartments.</p><p>Panzyga has an average half-life of about 26&ndash;39 days. This half-life may vary from patient to patient, in particular in primary immunodeficiency.<em> </em></p><p>IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.</p><p><u>Paediatric Population</u></p><p>The results of the pharmacokinetic studies in the different paediatric age groups are summarized in the following table, with a comparison to adults.</p><p>&nbsp;</p><p><em>Overview on Pharmacokinetic Characteristics of Total IgG for Panzyga Divided by Different Age Groups (median values)</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:518px"><tbody><tr><td rowspan="2"><p>&nbsp;</p></td><td rowspan="2"><p>&nbsp;</p></td><td colspan="2"><p><em>Paediatric Population</em></p></td><td rowspan="2"><p><em>Adults</em></p></td><td rowspan="3"><p><em>All Age Groups</em></p></td></tr><tr><td><p><em>Children</em></p></td><td><p><em>Adolescents</em></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&ge; 2 to &lt;12 yrs</p></td><td><p>&ge; 12 to &lt;16 yrs</p></td><td><p>&ge; 16 to &le;75 yrs</p></td></tr><tr><td><p><em>Parameter</em></p></td><td><p><em>Unit</em></p></td><td><p><em>N=13</em></p></td><td><p><em>N=12</em></p></td><td><p><em>N=26</em></p></td><td><p><em>N=51</em></p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub></p></td><td style="vertical-align:top"><p>g/L</p></td><td style="vertical-align:top"><p>18.6</p></td><td style="vertical-align:top"><p>19.3</p></td><td style="vertical-align:top"><p>17.1</p></td><td style="vertical-align:top"><p>18.2</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>min</sub></p><p>[range]</p></td><td style="vertical-align:top"><p>g/L</p></td><td style="vertical-align:top"><p>10.7</p><p>[7.2 &ndash; 16.8</p></td><td style="vertical-align:top"><p>9.3</p><p>[7.4 &ndash; 20.4]</p></td><td style="vertical-align:top"><p>10.1</p><p>[6.8 &ndash; 20.6]</p></td><td style="vertical-align:top"><p>9.9</p><p>[6.8 &ndash; 20.6]</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-tau</sub></p></td><td style="vertical-align:top"><p>h&middot;g/L</p></td><td style="vertical-align:top"><p>6957</p></td><td style="vertical-align:top"><p>6826</p></td><td style="vertical-align:top"><p>7224</p></td><td style="vertical-align:top"><p>7182</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>&frac12;</sub></p></td><td style="vertical-align:top"><p>days</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>36</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immunoglobulins are normal constituents of the human body.</p><p>The safety of Panzyga has been demonstrated in several non-clinical safety pharmacology (cardiovascular, respiratory, and bronchospastic effects, thrombogenic potential) and toxicology studies (acute toxicity, local tolerance). The non-clinical data reveal no special risk for humans based on these conventional safety pharmacology and toxicity studies. Studies of repeated dose toxicity, genotoxicity, and toxicity to reproduction in animals are impracticable due to induction of and interference by developing antibodies to heterologous proteins. Since clinical experience provides no evidence for carcinogenic potential of immunoglobulins, no experimental genotoxicity/carcinogenicity studies in heterogeneous species were performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glycine&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.3 mg/ml</p><p>Water for injections&nbsp;&nbsp;&nbsp; ad 1 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of incompatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C&ndash;8&deg;C). Do not freeze. Keep the container in the outer carton in order to protect from light.</p><p>The product may be stored at temperatures above +8&deg;C and below +25&deg;C for up to 6 months, without being refrigerated again during this period, and it must be discarded if not used after this.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pack sizes:</p><p>1 g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in a 20 ml vial</p><p>2.5 g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in a 30 ml vial</p><p>5 g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50 ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in a 70 ml bottle</p><p>10 g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 100 ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in a 100 ml bottle</p><p>20 g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 200 ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in a 250 ml bottle</p><p>30 g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 300 ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in a 300 ml bottle</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p><p>The vials/bottles are made of type II glass closed with bromobutyl rubber stoppers and sealed with aluminium flip-off caps.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The product should be brought to room or body temperature before use.</p><p>The solution should be clear or slightly opalescent and colourless or pale yellow.</p><p>Solutions that are cloudy or have deposits should be not used.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>Due to the possibility of bacterial contamination, any remaining contents must be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OCTAPHARMA AG
Seidenstrasse 2
8853 Lachen
Switzerland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>